3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Sarcoma
6
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Breast Neoplasms
4
Sarcoma, Ewing
3
Neoplasms
3
Insulin-Like Growth Factor I, Resistance To
3
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Lymphoma
2
Colonic Neoplasms
2
Carcinoid Tumor
2
Adenocarcinoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pathologic Complete Response
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Cisplatin
8
Carboplatin
8
Bevacizumab
8
Pleurodesis
7
Talc
6
Paclitaxel
6
Docetaxel
5
Povidone-Iodine
4
Doxycycline
4
Taxes
3
Gemcitabine
3
Drug Therapy
3
Chest Tubes
3
aldesleukin
2
Zoledronic Acid
2
Trastuzumab
2
Thoracoscopy
2
Sodium Chloride
2
Silver Nitrate
2
Pharmaceutical Preparations
2
Nivolumab
2
Interleukin-2
2
Fluorodeoxyglucose F18
2
Fentanyl
2
Erlotinib Hydrochloride
2
Cetuximab
2
Bortezomib
2
viscum album peptide
1
tocilizumab
1
tipifarnib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pleural Effusion, Malignant
×
ganitumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts